BNP assays: predicting the future of CHF patients.
Kinkade
Elizabeth
E
James Cancer Hospital and Research Institute, The Ohio State University Medical Center, Columbus, OH, USA.
Frazier
Susan K
SK
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D017281:Cost of Illness; D018450:Disease Progression; D004232:Diuretics / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D004359:Drug Therapy, Combination; D005260:Female; D016231:Fluorescence Polarization Immunoassay; D006333:Heart Failure / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood; D024802:Nurse's Role; D019095:Point-of-Care Systems; D011237:Predictive Value of Tests; D011320:Primary Health Care; D011379:Prognosis; D012016:Reference Values; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D004232:Diuretics; D020097:Natriuretic Peptide, Brain